Emily S. Lau

Emily S. Lau

Auto-generated profile, based on publicly available information

Emily S. Lau

Heart and Vascular Institute, Mass General Brigham

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2023 in Circulation
Verified
Journal Article
Closed access
LCLeslie Cho
Leslie Cho
AKAndrew M. Kaunitz
Andrew M. Kaunitz
SFStephanie S. Faubion
Stephanie S. Faubion
SHSharonne N. Hayes
Sharonne N. Hayes
ELEmily S. Lau
Emily S. Lau
FCfor the ACC CVD in Women Committee
for the ACC CVD in Women Committee
Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women’s health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.

30 November 2022 in Women's Health
Verified
Journal Article
Open access
GKGurleen Kaur
Gurleen Kaur
ELEmily Lau
Emily Lau
Heart failure with preserved ejection fraction has a higher prevalence in women versus men. There are several proposed mechanisms to explain this sex discrepancy including differences in cardiovascular adaptation to comorbidities and potential underlying etiologic mechanisms. In this review, we summarize sex differences in traditional risk factors, such as obesity, diabetes, hypertension, and coronary artery disease, which contribute to the development of heart failure with preserved ejection fraction in women. Furthermore, we explore female-specific risk factors, such as sex hormones, adverse pregnancy outcomes, and other reproductive factors, which may explain the predominance of heart failure with preserved ejection fraction in women. Beyond sex differences in risk factors, there are also significant sex differences in outcomes with women reporting lower quality of life but overall better survival versus men. Finally, while treatment options for patients with heart failure with preserved ejection fraction are still limited, sex differences have also been reported for the available therapies, with suggestion of preferential benefit of specific heart failure with preserved ejection fraction therapies in women. Further work is required to better understand sex differences in heart failure with preserved ejection fraction, including deeper understanding of pathophysiological mechanisms, derivation of more accurate risk stratification models, and increased representation of women in clinical trials.

6 November 2023 in JACC
Verified
Journal Article
Closed access
ELEmily S. Lau
Emily S. Lau
PAPaolo Di Achille
Paolo Di Achille
KKKavya Kopparapu
Kavya Kopparapu
CACarl T. Andrews
Carl T. Andrews
PSPulkit Singh
Pulkit Singh
JHJennifer E. Ho
Jennifer E. Ho

17 February 2022 in Circulation Research
Verified
Journal Article
Closed access
PDF file
ELEmily S. Lau
Emily S. Lau
ABAleksandra Binek
Aleksandra Binek
SPSarah J. Parker
Sarah J. Parker
SSSvati H. Shah
Svati H. Shah
MZMarkella V. Zanni
Markella V. Zanni
JHJennifer E. Ho
Jennifer E. Ho
Sex-based differences in cardiovascular disease presentation, diagnosis, and response to therapies are well established, but mechanistic understanding and translation to clinical applications are limited. Blood-based biomarkers have become an important tool for interrogating biologic pathways. Understanding sexual dimorphism in the relationship between biomarkers and cardiovascular disease will enhance our insights into cardiovascular disease pathogenesis in women, with potential to translate to improved individualized care for men and women with or at risk for cardiovascular disease. In this review, we examine how biologic sex associates with differential levels of blood-based biomarkers and influences the effect of biomarkers on disease outcomes. We further summarize key differences in blood-based cardiovascular biomarkers along central biologic pathways, including myocardial stretch/injury, inflammation, adipose tissue metabolism, and fibrosis pathways in men versus women. Finally, we present recommendations for leveraging our current knowledge of sex differences in blood-based biomarkers for future research and clinical innovation.

28 April 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ELEmily S. Lau
Emily S. Lau
JMJenna N. McNeill
Jenna N. McNeill
SPSamantha M. Paniagua
Samantha M. Paniagua
ELElizabeth E. Liu
Elizabeth E. Liu
JWJessica K. Wang
Jessica K. Wang
JHJennifer E. Ho
Jennifer E. Ho
Background: Men are at higher risk for serious complications related to COVID-19 infection than women. More robust immune activation in women has been proposed to contribute to decreased disease severity, although systemic inflammation has been associated with worse outcomes in COVID-19 infection. Whether systemic inflammation contributes to sex differences in COVID-19 infection is not known. Study design and methods: We examined sex differences in inflammatory markers among 453 men (mean age 61) and 328 women (mean age 62) hospitalized with COVID-19 infection at the Massachusetts General Hospital from March 8 to April 27, 2020. Multivariable linear regression models were used to examine the association of sex with initial and peak inflammatory markers. Exploratory analyses examined the association of sex and inflammatory markers with 28-day clinical outcomes using multivariable logistic regression. Results: Initial and peak CRP were higher in men compared with women after adjustment for baseline differences (initial CRP: ß 0.29, SE 0.07, p = 0.0001; peak CRP: ß 0.31, SE 0.07, p<0.0001) with similar findings for IL-6, PCT, and ferritin (p<0.05 for all). Men had greater than 1.5-greater odds of dying compared with women (OR 1.71, 95% CI 1.04–2.80, p = 0.03). Sex modified the association of peak CRP with both death and ICU admission, with stronger associations observed in men compared with women (death: OR 9.19, 95% CI 4.29–19.7, p <0.0001 in men vs OR 2.81, 95% CI 1.52–5.18, p = 0.009 in women, Pinteraction = 0.02). Conclusions: In a sample of 781 men and women hospitalized with COVID-19 infection, men exhibited more robust inflammatory activation as evidenced by higher initial and peak inflammatory markers, as well as worse clinical outcomes. Better understanding of sex differences in immune responses to COVID-19 infection may shed light on the pathophysiology of COVID-19 infection.

25 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JMJeanette Maier
Jeanette Maier
VAVicente Andrés
Vicente Andrés
SCSara Castiglioni
Sara Castiglioni
AGAlessandro Giudici
Alessandro Giudici
ELEmily S. Lau
Emily S. Lau
NHNaomi M. Hamburg
Naomi M. Hamburg
Vascular aging, i.e., the deterioration of the structure and function of the arteries over the life course, predicts cardiovascular events and mortality. Vascular degeneration can be recognized before becoming clinically symptomatic; therefore, its assessment allows the early identification of individuals at risk. This opens the possibility of minimizing disease progression. To review these issues, a search was completed using PubMed, MEDLINE, and Google Scholar from 2000 to date. As a network of clinicians and scientists involved in vascular medicine, we here describe the structural and functional age-dependent alterations of the arteries, the clinical tools for an early diagnosis of vascular aging, and the cellular and molecular events implicated. It emerges that more studies are necessary to identify the best strategy to quantify vascular aging, and to design proper physical activity programs, nutritional and pharmacological strategies, as well as social interventions to prevent, delay, and eventually revert the disease.